Matches in Wikidata for { <http://www.wikidata.org/entity/Q90869309> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q90869309 description "article scientifique publié en 2019" @default.
- Q90869309 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90869309 description "scientific article published on 22 October 2019" @default.
- Q90869309 description "wetenschappelijk artikel" @default.
- Q90869309 description "наукова стаття, опублікована 22 жовтня 2019" @default.
- Q90869309 name "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 name "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 type Item @default.
- Q90869309 label "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 label "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 prefLabel "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 prefLabel "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 P1433 Q90869309-C1908163-FFBA-45E2-8BED-0DA1A58DA5E3 @default.
- Q90869309 P1476 Q90869309-5D18BBD1-5D44-4D12-BEDA-BA51853A0631 @default.
- Q90869309 P2093 Q90869309-0ADD6D49-864E-44D9-9FDA-E5C315FE6CED @default.
- Q90869309 P2093 Q90869309-1549C121-B05F-49E3-A2AA-E4BED4A9DE27 @default.
- Q90869309 P2093 Q90869309-1B7B3090-6F0C-446F-A7B6-F40FFFDC10F2 @default.
- Q90869309 P2093 Q90869309-2051F633-D02D-4335-8963-65F78AA253B3 @default.
- Q90869309 P2093 Q90869309-2DFD0A9C-60B5-465E-9601-E7E17CACF595 @default.
- Q90869309 P2093 Q90869309-36BE99E1-B749-4DDA-886B-CA312153F137 @default.
- Q90869309 P2093 Q90869309-7FAE24F2-63AE-4A01-BE9F-9206DEEDC47A @default.
- Q90869309 P2093 Q90869309-DDC055A2-4390-4A6A-9206-9671B334E4E7 @default.
- Q90869309 P2093 Q90869309-F40A8A4D-5F50-48A9-9670-BB88BC9F60A4 @default.
- Q90869309 P2093 Q90869309-F91416C5-FB2A-479F-BA3C-2D5BE662CA8D @default.
- Q90869309 P2093 Q90869309-FF148BFA-24A5-4961-B194-4259E02C504A @default.
- Q90869309 P304 Q90869309-F990512E-945C-4807-AC3E-5485E1BD4587 @default.
- Q90869309 P31 Q90869309-2095EE54-B66B-4052-BCC8-C64EEB2F0ADB @default.
- Q90869309 P356 Q90869309-8B75ED5D-B197-4130-9014-68B5D048B64D @default.
- Q90869309 P478 Q90869309-B8190107-DC33-4B0F-82D0-742449A99CB0 @default.
- Q90869309 P50 Q90869309-523FA22D-3433-47D5-B374-EF0AC1423BF8 @default.
- Q90869309 P50 Q90869309-9744B987-A8A7-46C9-A427-3F6B40B67AB1 @default.
- Q90869309 P50 Q90869309-E7CB183E-43CF-424E-BD6E-A4420F552845 @default.
- Q90869309 P577 Q90869309-E61ECF76-D037-46E2-897C-96C1CB917234 @default.
- Q90869309 P698 Q90869309-76B4C32C-AC92-4ED8-BBE8-0BAA84461BFB @default.
- Q90869309 P921 Q90869309-606F6B51-EBCD-4740-8DB9-9CAC96E0DAA6 @default.
- Q90869309 P356 BJU.14876 @default.
- Q90869309 P698 31638341 @default.
- Q90869309 P1433 Q4835773 @default.
- Q90869309 P1476 "TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)" @default.
- Q90869309 P2093 "ANZUP TheraP team" @default.
- Q90869309 P2093 "Alison Y Zhang" @default.
- Q90869309 P2093 "Amir Iravani" @default.
- Q90869309 P2093 "Andrew Martin" @default.
- Q90869309 P2093 "Arun Azad" @default.
- Q90869309 P2093 "Ian D Davis" @default.
- Q90869309 P2093 "John Violet" @default.
- Q90869309 P2093 "Margaret McJannett" @default.
- Q90869309 P2093 "Martin Stockler" @default.
- Q90869309 P2093 "Nicola J Lawrence" @default.
- Q90869309 P2093 "Scott Williams" @default.
- Q90869309 P304 "5-13" @default.
- Q90869309 P31 Q13442814 @default.
- Q90869309 P356 "10.1111/BJU.14876" @default.
- Q90869309 P478 "124 Suppl 1" @default.
- Q90869309 P50 Q53198887 @default.
- Q90869309 P50 Q58211989 @default.
- Q90869309 P50 Q61872967 @default.
- Q90869309 P577 "2019-10-22T00:00:00Z" @default.
- Q90869309 P698 "31638341" @default.
- Q90869309 P921 Q42824440 @default.